Can two drugs reboot radioiodine therapy for tough thyroid cancers?
NCT ID NCT04462471
First seen Jun 25, 2026 · Last updated Jun 26, 2026 · Updated 1 time
Summary
This early-phase trial tested two drugs, vemurafenib and copanlisib, in 8 people with advanced BRAF-mutant thyroid cancers that had stopped responding to radioiodine therapy. The goal was to see if the combination could make tumors sensitive to radioiodine again and to find the safest dose. The study focused on safety and dosing, not yet on how well it works.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- vemurafenib and copanlisib
- What this could lead to
- If successful, this combination could help radioiodine therapy shrink tumors in people with BRAF-mutant thyroid cancers that no longer respond to standard radioiodine treatment.
- What could go wrong
- This is a very early phase 1 trial with only 8 participants, focused on finding safe doses. It is not yet known if the combination will actually improve treatment outcomes or cause serious side effects.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BRAF V600E MUTATION POSITIVE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Memorial Sloan Kettering Basking Ridge (Limited Protocol Activities)
Basking Ridge, New Jersey, 07920, United States
-
Memorial Sloan Kettering Bergen (Limited Protocol Activities)
Montvale, New Jersey, 07645, United States
-
Memorial Sloan Kettering Cancer Center @ Commack (Limited Protocol Activities)
Commack, New York, 11725, United States
-
Memorial Sloan Kettering Monmouth (Limited protocol activities)
Middletown, New Jersey, 07748, United States
-
Memorial Sloan Kettering Nassau (Limited protocol activities)
Rockville Centre, New York, 11553, United States
-
Memorial Sloan Kettering Westchester (Limited protocol activities)
Harrison, New York, 10604, United States
-
Memorial Sloan-Kettering Cancer Center (All protocol activities)
New York, New York, 10065, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Genetic test may spare patients from unnecessary thyroid surgery
- Can a new oral drug outsmart Radioiodine-Resistant thyroid cancer?
- Can an immune booster make radioiodine more effective against thyroid cancer?
- Hidden thyroid cancers may be more common in Graves' disease than thought
- Can math make thyroid hormone therapy more precise?
- Can AI help surgeons see thyroid cancer more clearly?